Careers
Contact Us
Navigate Adaptimmune Limited
Home
Our Company
Overview
Board of Directors
Management & Founders
Partners
Pipeline
Overview
MAGE-A10 TCR
AFP TCR
MAGE-A4 TCR
NY-ESO TCR
Technology
Overview
The Immune System
Our Engineered T-Cell Therapies
Our Technology Platform
Manufacturing
Intellectual Property
Publications
Patients & Families
Overview
Our Clinical Trials
Clinical Trial FAQ
Cancer Information
NEW
Cancer Immunotherapy Month
News & Events
News
Scientific Conferences
Investor Conferences
Investors
Focusing on the needs of our patients
Learn More
Enhancing the Affinity of T-cell to Fight Cancer
Learn More
Investigating SPEAR T-Cell Therapy in 8 Solid Tumors
Learn More
Working with Leading Experts to Transform T-cell Therapy for Cancer Patients
Learn More
Latest News •
View all
July 18, 2018
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
June 11, 2018
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
June 4, 2018
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
Adaptimmune on Linkedin
Adaptimmune on Twitter
Tweets by Adaptimmune
The Immune System
Clinical Trials
Our Pipeline
Manufacturing
Partnerships
